“Some people think our stock price at 40c is too high but the commercialisation that is coming will make their heads spin” so said Brian Leedman towards the end of his Resapp presentation. Truely Brian could sell ice to the eskimos.
It was great to catch up with some HotCopper Rappers, @Red bar, @RNClark, @Rudy1 and others. I wasn’t taking notes, but besides the quote above, Brian indicated that a Chinese partnership wouldn’t necessarily use the app as a diagnostic tool; rather as a ‘screening’ tool which wouldn’t need CFDA approval. Brian intimated he would accept a lower fee per cough ($2??) but that would get revenues happening faster than a much longer pathway involving Chinese clinical trials.
Regarding potential commercial contracts Brian told us earlier “to expect the unexpected” with a grin on his face. He also personally believes the sleep apnea diagnosis capacity will outweigh the coughing revenue potential. Red Bar had a number of questions so he will chime in later, and if I can think of more I will post again.
RAP Price at posting:
38.0¢ Sentiment: Buy Disclosure: Held
